Kuvan

Sapropterin dihydrochloride, the active ingredient in Kuvan, is a synthetic tetrahydrobiopterin (BH4) presented as an oral tablet for oral use. It is indicated for the treatment of phenylketonuria (PKU) in patients who respond to tetrahydrobiopterin and for managing hyperphenylalaninemia, helping to lower elevated blood phenylalanine levels.

GNH USA supplies Kuvan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. All batches meet EU GMP requirements and are shipped with full documentation to support regulatory compliance, ensuring consistent potency and safety for patients.

Kuvan is employed in the management of phenylalanine‑related metabolic disorders, primarily within the phenylketonuria therapeutic pathway.

Phenylketonuria (PKU): reduces blood phenylalanine concentrations in patients who are responsive to tetrahydrobiopterin. Hyperphenylalaninemia: lowers elevated phenylalanine levels, helping to prevent neurocognitive complications. Tetrahydrobiopterin‑responsive metabolic conditions: improves phenylalanine metabolism, supporting dietary management.

Adverse reactions to Kuvan are generally mild, but serious events can occur and require medical attention.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: occasional, often transient. - Abdominal pain: mild discomfort. - Rash: skin irritation or erythema. - Fatigue: reduced energy levels. - Vomiting: occasional episodes.

Serious or Rare Side Effects: - Hypersensitivity reactions: including angioedema or anaphylaxis. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Liver enzyme elevation: potential hepatic involvement. - Thrombocytopenia: reduced platelet count. - Acute renal impairment: rare kidney function changes.

Before initiating therapy, clinicians should assess patient‑specific factors and monitor for potential risks.

Pregnancy: Category B – use only if the potential benefit justifies the potential risk to the fetus. Breastfeeding: Caution – monitor infant for any adverse effects. Renal impairment: Adjust dose and monitor phenylalanine levels closely. Age: Safety not established in children under 4 years of age. Drug interactions: Review concomitant medications for possible interactions. Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Kuvan may interact with other agents that influence phenylalanine metabolism or cofactor pathways.

Major Interactions (Avoid): - Phenylalanine‑rich protein supplements: may counteract the drug’s effect. - Monoamine oxidase inhibitors: potential for increased neurotransmitter levels.

Moderate Interactions (Monitor Closely): - Antiepileptic drugs: may alter phenylalanine metabolism. - Vitamin B6 supplements: could affect cofactor activity. - Oral contraceptives: monitor phenylalanine concentrations during therapy.